Jupiter Neurosciences, Inc. (JUNS)
NASDAQ: JUNS · Real-Time Price · USD
0.2310
-0.0111 (-4.58%)
At close: Jun 8, 2026, 4:00 PM EDT
0.2350
+0.0040 (1.73%)
After-hours: Jun 8, 2026, 7:59 PM EDT
Jupiter Neurosciences Revenue
Jupiter Neurosciences had revenue of $18.65K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $40.45K. In the year 2025, Jupiter Neurosciences had annual revenue of $21.80K.
Revenue (ttm)
$40.45K
Revenue Growth
n/a
P/S Ratio
248.00
Revenue / Employee
$8,090
Employees
5
Market Cap
10.03M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.80K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 233.28K | -404.76K | -63.44% |
| Dec 31, 2021 | 638.04K | -488.20K | -43.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HCW Biologics | 6.59M |
| Immuron | 4.99M |
| SeaStar Medical Holding | 1.44M |
| BioRestorative Therapies | 357.87K |
| Kiora Pharmaceuticals | 20.00K |
| BioCardia | 3.00K |
JUNS News
- 12 days ago - Jupiter Neurosciences commences patient enrollment in RESET trial - TheFly
- 12 days ago - Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease - GlobeNewsWire
- 13 days ago - D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering - Accesswire
- 18 days ago - Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering - GlobeNewsWire
- 19 days ago - Jupiter Neurosciences announces pricing of $2M registered direct offering - TheFly
- 19 days ago - Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering - GlobeNewsWire
- 19 days ago - Jupiter Neurosciences to acquire licensing rights to ALA-002 for $3.33M upfront - TheFly
- 19 days ago - Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech - GlobeNewsWire